MK-0518. HIV integrase inhibitor

Drugs of the Future

Volumn 32, Issue 2, 2007, Pages 118-122

  Wang, Y ^a   Serradell, N ^b   Bolos J ^b   Rosa, E ^b  

^a Prous Science ^*  (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BMS 707035; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GS 9137; GS 9224; INTEGRASE INHIBITOR; JTK 303; L 900612; MIDAZOLAM; MK 0518; PLACEBO; RALTEGRAVIR POTASSIUM; RIFAMPICIN; RITONAVIR; S 364735; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERANCE; ENZYME INHIBITION; FATIGUE; FLUSHING; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INJECTION SITE REACTION; MONOTHERAPY; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

EID: 34247524127     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.02.1076305     Document Type: Review

References (29)

1. Belyk, K.M., Morrison, H.G., Jones, P., Summa, V. (Merck & Co., Inc.; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.). Potassium salt of an HIV integrase inhibitor. US 2006122205, WO 2006060712, WO 2006060730.
2. Summa, V., Pace, P., Petrocchi, A. et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in phase III clinical trials. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst THPE0020.
3. Summa, V. Discovery, synthesis and optimization of a new series of selective HIV integrase inhibitors leading to MK-0518 currently in phase III clinical trial for treatment of HIV/AIDS. 232nd ACS Natl Meet (Sept 10-14, San Francisco) 2006, Abst MEDI-298.
4. Lataillade, M., Kozal, M.J. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDs 2006, 20(7): 489-501.
5. LaFemina, R.L., Schneider, C.L., Robbins, H.L. et al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992, 66(12): 7414-9.
6. Farnet, C.M., Haseltine, W.A. Integration of HIV-1 DNA in vitro. Proc Natl Acad Sci USA 1990, 87(11): 4164-8.
7. Brown, P.O. Integration of retroviral DNA. Curr Topcis Microbiol Immunol 1990, 157: 19-47.
8. Van Male, B., Debyser, Z. HIV-1 integration: An interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev 2005, 7(1): 26-43.
9. Hazuda, D.J., Felock, P., Witmer, M. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287: 646-50.
10. Miller, M., Witmer, M., Stillmock, K. et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst THPE0302.
11. Gonzalez-Paz, O., Taliani, M., Di Marco, A. et al. Preclinical pharmacokinetics and metabolism of MK-0518, a potent HIV integrase inhibitor in phase III clinical trials. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst THPE0027.
12. Laufer, R., Taliani, M., DiMarco, A. et al. Prediction of human pharmacokinetics for a series of potent and selective HIV integrase inhibitors leading to development of MK-0518 for the treatment of AIDS. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst CDA0141.
13. Petry, A.S., Wenning, L.A., Laethem, M. et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-376.
14. Kassahun, K., McIntosh, I., Hreniuk, D. et al. Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-372.
15. Markowitz, M., Morales-Ramirez, J.O., Nguyen, B.-Y et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006, 43(5): 509-15.
16. Markowitz, M., Nguyen, B.-Y., Gotuzzo, E. et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst THLB0214.
17. Teppler, H., Azrolan, N., Chen, J., Nguyen, B. Differential effect of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ART)-naive patients. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst H-256a.
18. Grinsztejn, B., Nguyen, B., Katlama, C. et al. Potent efficacy of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus: 24-Week data. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst H-1670b.
19. Grinsztejn, B., Nguyen, B.Y., Katlama, C. et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 13th Conf Retroviruses Opportunistic Infect (CROI) (Feb 5-9, Denver) 2006, Abst 159LB.
20. A study to evaluate the safety and efficacy of MK-0518 in HIV-infected patients failing current antiretroviral therapies (NCT00293254). ClinicalTrials.gov Web site, February 15, 2007.
21. A study to evaluate the safety and efficacy of MK-0518 in HIV-infected patients failing current antiretroviral therapies (NCT00293267). ClinicalTrials.gov Web site, February 15, 2007.
22. Early access of MK0518 in combination with an optimized background antiretroviral therapy (NCT00377065). ClinicalTrials.gov Web site, February 15, 2007.
23. A study to evaluate the safety and antiretroviral activity of MK0518 versus efavirenz in treatment naive HIV-infected patients, each in combination with TRUVADA™ (NCT00369941). ClinicalTrials.gov Web site, February 15, 2007.
24. Iwamoto, M., Wenning, L.A., Petry, A.S. et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PD) of MK-0518. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-373.
25. Wenning, L.A., Hanley, H., Stone, J. et al. Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-374.
26. Wenning, L.A., Friedman, E., Kost, J.T. et al. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF). 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-375.
27. Mistry, G.C., Wenning, L.A., Merschman, S. et al. Atazanavir and ritonavir increase plasma levels of MK-0518. 8th Int Congr Drug Ther HIV Infect (Nov 12-16, Glasgow) 2006, Abst P291.
28. Iwamoto, M., Wenning, L.A., Liou, S.Y. et al. Rifampin (RIF) modestly reduces plasma levels of MK-0518. 8th Int Congr Drug Ther HIV Infect (Nov 12-16, Glasgow) 2006, Abst P299.
29. Iwamoto, M., Wenning, L.A., Troyer, M.D. et al. Lack of a pharmacokinetic interaction of MK-0518 on midazolam (MDZ). 8th Int Congr Drug Ther HIV Infect (Nov 12-16, Glasgow) 2006, Abst P300.